T. Rowe Price Investment Management, Inc. 13D and 13G filings for Ascendis Pharma A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:28 pm Sale |
2024-09-30 | 13G | Ascendis Pharma A/S ASND |
T. Rowe Price Investment Management, Inc. | 1,765,042 2.900% |
-2,224,788 (-55.76%) |
Filing |
| 2024-02-14 10:04 am Purchase |
2023-12-31 | 13G | Ascendis Pharma A/S ASND |
T. Rowe Price Investment Management, Inc. | 3,989,830 6.900% |
3,989,830 (New Position) |
Filing |